

Evaluation of Olfactory Bulb Volumes in Patients With Rheumatoid Arthritis: A Retrospective Study

Selçuk SAYILIR¹, Neşat ÇULLU², Gönen MENGİ³, Timur EKİZ⁴

¹Department of Physical Medicine and Rehabilitation, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey

²Department of Radiology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey

³Department of Rheumatology, Muğla Sıtkı Koçman University Faculty of Medicine, Muğla, Turkey

⁴Department of Physical Medicine and Rehabilitation, Dermancan Medical Center, Adana, Turkey

ABSTRACT

Objectives: This study aims to evaluate olfactory bulb (OB) volume in patients with rheumatoid arthritis (RA) using magnetic resonance imaging.

Patients and methods: In this retrospective and case-control study, OB volumes of 37 RA patients (6 males, 31 females; mean age 48.6±10.8 years; range, 18 to 65 years) were compared with those of 36 healthy control subjects (5 males, 31 females; mean age 46.5±6.9 years; range, 22 to 62 years). OB images were gained with a protocol of 256×256 matrix and a 24-cm field of view, repetition time=5000 milliseconds (TR 5000 msec), echo time=130 milliseconds (TE 130 msec), number of excitations=2 (NEX 2) and a 5 mm slice thickness. OB volume was computed with the aid of the above images using three dimensional views. The surface of each slice area was calculated in mm² and all surfaces were added and multiplied by front-back length to obtain a volume in mm³.

Results: Left (70.5±14.4 vs. 91.1±12.2 mm³), right (73.9±15.1 vs. 91.2±12.4 mm³), and total (144.5±27.4 vs. 182.8±21.5 mm³) OB volumes were significantly lower in the RA group than in the control group (all p<0.05).

Conclusion: Patients with RA may be under risk of decreased OB volumes and related impaired odor functions which might affect the quality of life and activities of daily living adversely.

Keywords: Magnetic resonance imaging, olfactory bulb volume, rheumatoid arthritis.

Olfactory perception plays an important role to provide environmental communication of the human being. Some specific localizations in the central nervous system are specialized for olfactory functions such as detection, perception and identification of the odor. The olfactory bulb (OB) is the first step of transmission of the olfactory pathway, and it is located bilaterally in the olfactory cortex, hypothalamus, amygdala, and basal telencephalon.^{1,2} The neural progenitor cells have roles of dynamic changes such as neuroplastic changes and synaptogenesis in the OB in respect of the olfactory functions throughout

life as shown in previous animal studies.³ Some psychiatric and neurologic disorders, including depression, Alzheimer's disease, schizophrenia, and Parkinson's disease may be related to olfactory dysfunction or decreased volume of the OB.⁴⁻⁶ Moreover, decreased OB volume has been shown in some autoimmune diseases.⁷⁻¹⁰ Magnetic resonance imaging (MRI) studies have demonstrated decreased OB volumes in patients with olfactory dysfunction as well.¹¹ Although impaired olfactory functions such as discrimination, identification, and threshold of the odor have been reported by using self-reported

Received: November 24, 2017 **Accepted:** February 10, 2019 **Published online:** April 18, 2019

Correspondence: Selçuk Sayılır, MD. Muğla Sıtkı Koçman Üniversitesi Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, 48000 Gülağzı, Muğla, Turkey.
Tel: +90 252 - 214 13 26 e-mail: selcuksay@gmail.com

Citation:

Sayılır S, Çullu N, Mengi G, Ekiz T. Evaluation of olfactory bulb volumes in patients with rheumatoid arthritis: a retrospective study. Arch Rheumatol 2019;34(x):i-iv.

olfactory status with subjective olfactory tests in patients with rheumatoid arthritis (RA),¹² to our knowledge, OB volumes have not been studied in RA patients yet. Therefore, in this study, we aimed to evaluate OB volume in patients with RA using MRI.

PATIENTS AND METHODS

This retrospective and case-control study was conducted at Muğla Sıtkı Koçman University Training and Research Hospital between May 2013 and May 2017. OB volumes of 37 RA patients (6 males, 31 females; mean age 48.6 ± 10.8 years; range, 18 to 65 years) were compared with those of 36 healthy age and sex-matched control subjects (5 males, 31 females; mean age 46.5 ± 6.9 years; range, 22 to 62 years). Subjects who had any of the following criteria were excluded: brain injury or trauma, depression or other psychiatric conditions, endocrinologic problems, neurological disorders, or chronic sinusitis/rhinitis. Subjects older than 65 years were excluded in respect of age-related degeneration of the OB.¹³ The study protocol was approved by the Muğla Sıtkı Koçman University Clinical Research Ethics Committee (28.09.2017-16/1). Since the data were obtained retrospectively, this study protocol does not require to obtain written informed consent from the participants. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Olfactory bulb volumes were measured using cranial MRI examinations. Total OB volume refers to the sum of the right and left OB volumes. MRI evaluations were performed with a 1.5-T scanner (GE Healthcare's Signa HDxt 1.5T MRI scanner, Waukesha, Wisconsin, USA). Images were gained with a protocol of 256×256 matrix and a 24-cm

field of view, repetition time=5000 milliseconds (TR 5000 msec), echo time=130 milliseconds (TE 130 msec), number of excitations=2 (NEX 2) and a 5-mm slice thickness. OB volume was computed with the aid of the above images using three dimensional views. The volumetric evaluations were calculated by a 10-year experienced radiologist who was blinded to the subjects. An electronic cursor was used for manually delineating the contours of OB (Figure 1). The surface of the each slice area was calculated in mm^2 and all surfaces were added and multiplied by front-back length to obtain a volume in mm^3 . Mean of the three consecutive measurements was taken into account. The observer established the minimum of the three consecutive measurements for measuring the MRI images. The intraobserver variability was determined at less than 5%.

Statistical analysis

Statistical assessments were performed using the IBM SPSS version 20.0 software (IBM Corp., Armonk, NY, USA). Descriptive data were shown as mean \pm standard deviation. Normal distribution was checked with the Shapiro-Wilk test. Independent samples t-test was used for evaluating the statistical differences between the groups and a p value of 0.05 was accepted as statistically significant.

RESULTS

Left (70.5 ± 14.4 vs. 91.1 ± 12.2 mm^3), right (73.9 ± 15.1 vs. 91.2 ± 12.4 mm^3), and total (144.5 ± 27.4 vs. 182.8 ± 21.5 mm^3) OB volumes were significantly lower in the RA group than in the control group (all $p < 0.05$) (Table 1).

Table 1. Comparison of olfactory bulb volumes between study groups

Variable	RA group (n=37)	Control group (n=36)	<i>p</i>
	Mean \pm SD	Mean \pm SD	
Age (year)	48.6 \pm 10.8	46.5 \pm 6.9	0.319
Right olfactory bulb (mm^3)	73.9 \pm 15.1	91.2 \pm 12.4	<0.001
Left olfactory bulb (mm^3)	70.5 \pm 14.4	91.1 \pm 12.2	<0.001
Total olfactory bulb (mm^3)	144.5 \pm 27.4	182.8 \pm 21.5	<0.001

SD: Standard deviation; RA: Rheumatoid arthritis.




Figure 1. Olfactory bulb measurement with magnetic resonance imaging. Coronal T₂-weighted view shows example measuring of olfactory bulb surface area.

DISCUSSION

In this study, we aimed to explore whether OB volume of RA patients differ from healthy subjects for the first time in the literature, to the best of our knowledge. The main finding of our study was that RA patients had decreased OB volumes.

Previous studies showed that impaired olfactory and gustatory functions affect adversely the quality of life.¹² In addition, decreased OB volumes are closely associated with impaired olfactory functions (i.e. odor identification, threshold, and discrimination).¹¹ OB can play a role in the stability of the inflammatory responses of the central nervous system. A significant decrease in interleukin (IL)-10 and increase in IL-1b after bullectomy have been shown in animal models.¹⁴ From this point of view, an increased inflammatory response of the central nervous system might eventually cause a decrease in OB volumes in RA.

Systemic corticosteroid utilization may be associated with sodium/water retention and may cause hypokalemic alkalosis which can cause reduced olfactory function.¹⁵ In addition, chemotherapeutic agents such as cyclophosphamide, methotrexate, and 5-fluorouracil, which are some medical agents for RA treatment, have been associated with impaired olfactory functions.¹⁶ Therefore,

prolongation of the impaired olfactory functions due to utilization of the aforementioned medical treatments may result in decreased OB volumes in RA patients.

Recently, animal studies have reported that olfactory ecto-mesenchymal stem cells (OMSCs), a new type of resident stem cell in the olfactory lamina propria, can express IL-10 and transforming growth factor-beta. In culture, immunosuppressive effects of OMSCs are associated with suppressing of effector T cell proliferation and increasing regulatory T cell development. Transfer of OMSCs reduced arthritis onset and severity, which was accompanied by increased regulatory T cells and reduced T helper type 1 (Th1)/Th17 cell responses *in vivo*.¹⁷ Therefore, impaired OMSCs functionality may accompany RA which may decrease OMSCs transforming/olfactory functions and related lower OB volumes.

The relationship between reduced OB volumes and neurodegenerative disorders has been investigated in the literature⁷ and it has been reported that the effect of the chronic systemic inflammation can play a role in neurodegenerative processes.¹⁸ Nevertheless, decreased OB volumes in patients with RA can be related to chronic systemic inflammation-associated neurodegenerative processes.

This study has some significant limitations. Our sample size was relatively small and we could not perform analysis for the diagnostic use of OB volume. Lack of performing odor tests (e.g. Sniffin' Sticks or The University of Pennsylvania Smell Identification Test) is another limitation. Finally, since the data were obtained retrospectively and patients had multiple admissions, we could not obtain sufficient formal and proper data concerning the disease activity, medications, autoantibodies, serologic tests, or systemic involvements.

In conclusion, patients with RA can be under risk of decreased OB volumes and related impaired odor functions which might affect the quality of life and activities of daily living adversely.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. Rolls ET. Taste, olfactory, and food texture processing in the brain, and the control of food intake. *Physiol Behav* 2005;85:45-56.
2. Martinez-Marcos A. On the organization of olfactory and vomeronasal cortices. *Prog Neurobiol* 2009;87:21-30.
3. Korol DL, Brunjes PC. Unilateral naris closure and vascular development in the rat olfactory bulb. *Neuroscience* 1992;46:631-41.
4. Doty RL. Olfaction in Parkinson's disease and related disorders. *Neurobiol Dis* 2012;46:527-52.
5. Moberg PJ, Kamath V, Marchetto DM, Calkins ME, Doty RL, Hahn CG, et al. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis. *Schizophr Bull* 2014;40:50-9.
6. Ortega-Hernandez OD, Kivity S, Shoenfeld Y. Olfaction, psychiatric disorders and autoimmunity: is there a common genetic association? *Autoimmunity* 2009;42:80-8.
7. Demarquay G, Ryvlin P, Royet JP. Olfaction and neurological diseases: a review of the literature. *Rev Neurol (Paris)* 2007;163:155-67. [Abstract]
8. Strous RD, Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. *Autoimmun Rev* 2006;6:54-60.
9. Leon-Sarmiento FE, Bayona EA, Bayona-Prieto J, Osman A, Doty RL. Profound olfactory dysfunction in myasthenia gravis. *PLoS One* 2012;7:e45544.
10. Shoenfeld Y. To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. *J Autoimmun* 2007;28:165-9.
11. Rombaux P, Duprez T, Hummel T. Olfactory bulb volume in the clinical assessment of olfactory dysfunction. *Rhinology* 2009;47:3-9.
12. Steinbach S, Proft F, Schulze-Koops H, Hundt W, Heinrich P, Schulz S, et al. Gustatory and olfactory function in rheumatoid arthritis. *Scand J Rheumatol* 2011;40:169-77.
13. Buschhüter D, Smitka M, Puschmann S, Gerber JC, Witt M, Abolmaali ND, et al. Correlation between olfactory bulb volume and olfactory function. *Neuroimage* 2008;42:498-502.
14. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. *Neurosci Biobehav Rev* 2005;29:627-47.
15. Stanbury RM, Graham EM. Systemic corticosteroid therapy--side effects and their management. *Br J Ophthalmol* 1998;82:704-8.
16. Steinbach S, Hummel T, Böhner C, Berkold S, Hundt W, Kriner M, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. *J Clin Oncol* 2009;27:1899-905.
17. Rui K, Zhang Z, Tian J, Lin X, Wang X, Ma J, et al. Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis. *Cell Mol Immunol* 2016;13:401-8.
18. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. *Nat Rev Immunol* 2007;7:161-7.